Heart disease is a common challenge for dogs, affecting about 10% of dogs over their lifetime. Among the most frequent culprits are myxomatous mitral valve disease (MMVD) and dilated cardiomyopathy (DCM), both of which can progress to congestive heart failure (CHF), where the heart struggles to pump blood effectively.

Boehringer Ingelheim has unveiled VETMEDIN® Solution, the first FDA-approved oral liquid treatment for managing CHF in dogs caused by MMVD or DCM. This new option offers a convenient and precise way to support canine heart health, especially for dogs that may struggle with tablets. Previous studies have demonstrated VETMEDIN®'s ability to enhance survival time and quality of life in dogs with these conditions.

The liquid formulation, now available in the U.S., provides the same proven dual-action benefits as the chewable tablets. It is flavorless, administered twice daily, and is especially suited for small dogs or those requiring easier dosing.

“Some dogs and pet owners may prefer a liquid medication, especially for smaller breeds," said Daniel Watkins, VP of U.S. Pet Business at Boehringer Ingelheim. "With VETMEDIN® Solution, we can help more dogs with heart disease live longer, better lives."

Important Safety Information:
VETMEDIN® Solution is indicated for dogs with clinical signs of heart failure and should not be used in cases of hypertrophic cardiomyopathy, aortic stenosis, or other conditions where increasing cardiac output is contraindicated. For full safety and prescribing details, visit Vetmedinclinic.com.

Since its introduction 25 years ago, VETMEDIN® has added more than one million years of extra life to dogs worldwide. Now, this liquid solution continues the legacy, ensuring that pet owners and their dogs have even more time to share.

For more details on VETMEDIN® Solution, visit Boehringer Ingelheim Animal Health.